
FDA Approves Blood-Test-Guided Switch to Camizestrant
The FDA granted accelerated approval to AstraZeneca's camizestrant for certain adults with advanced or metastatic HR-positive, HER2-negative breast cancer whose ESR1 mutation is detected during treatment through an FDA-approved test.







